EMAIL THIS PAGE TO A FRIEND

Human molecular genetics

Pharmacologic rescue of axon growth defects in a human iPSC model of hereditary spastic paraplegia SPG3A.


PMID 24908668

Abstract

Hereditary spastic paraplegias are a large, diverse group of neurological disorders (SPG1-71) with the unifying feature of prominent lower extremity spasticity, owing to a length-dependent axonopathy of corticospinal motor neurons. The most common early-onset form of pure, autosomal dominant hereditary spastic paraplegia is caused by mutation in the ATL1 gene encoding the atlastin-1 GTPase, which mediates homotypic fusion of ER tubules to form the polygonal ER network. We have identified a p.Pro342Ser mutation in a young girl with pure SPG3A. This residue is in a critical hinge region of atlastin-1 between its GTPase and assembly domains, and it is conserved in all known eukaryotic atlastin orthologs. We produced induced pluripotent stem cells from skin fibroblasts and differentiated these into forebrain neurons to generate a human neuronal model for SPG3A. Axons of these SPG3A neurons showed impaired growth, recapitulating axonal defects in atlastin-1-depleted rat cortical neurons and impaired root hair growth in loss-of-function mutants of the ATL1 ortholog rhd3 in the plant Arabidopsis. Both the microtubule cytoskeleton and tubular ER are important for mitochondrial distribution and function within cells, and SPG3A neurons showed alterations in mitochondrial motility. Even so, it is not clear whether this change is involved in disease pathogenesis. The SPG3A axon growth defects could be rescued with microtubule-binding agents, emphasizing the importance of tubular ER interactions with the microtubule cytoskeleton in hereditary spastic paraplegia pathogenesis. The prominent alterations in axon growth in SPG3A neurons may represent a particularly attractive target for suppression in screens for novel pharmacologic agents.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV100591
Anti-NANOG (AB1) antibody produced in rabbit, affinity isolated antibody
AV47988
Anti-NANOG (AB2) antibody produced in rabbit, affinity isolated antibody
SAB2500670
Anti-NANOG antibody produced in goat, affinity isolated antibody, buffered aqueous solution
N4413 Anti-Nanog antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB4300680
Anti-Nanog antibody produced in rabbit, affinity isolated antibody
SAB3500389
Anti-NANOG antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2104002
Anti-NANOG antibody produced in rabbit, affinity isolated antibody
SAB2104004
Anti-NANOG, (N-terminal) antibody produced in rabbit, affinity isolated antibody
HPA003895
Anti-REEP5 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2900736 Anti-REEP5 antibody produced in rabbit, affinity isolated antibody
HPA017311
Anti-SPAST antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2102978
Anti-TBR1 antibody produced in rabbit, affinity isolated antibody
SAB2701324
Anti-TBR1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2105287
Anti-TBR1, (N-terminal) antibody produced in rabbit, affinity isolated antibody
N3038
Monoclonal Anti-Nanog antibody produced in mouse, ~2 mg/mL, clone NNG-811, purified immunoglobulin, buffered aqueous solution
WH0079923M1
Monoclonal Anti-NANOG antibody produced in mouse, clone 2C11, purified immunoglobulin, buffered aqueous solution
SAB1405280
Monoclonal Anti-NANOG antibody produced in mouse, clone 2E11, purified immunoglobulin, buffered aqueous solution